ERBB2mRNA expression and response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-positive breast cancer

Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the res...

Descripción completa

Detalles Bibliográficos
Autores: Griguolo, Gaia, Brasó-Maristany, Fara, González Farré, Blanca, Pascual, Tomás, Chic Ruché, Núria, Saurí, Tamara, Kates, Ronald, Gluz, Oleg, Martínez, Débora, Paré, Laia, Tsvetkova, Vassilena, Pesantez, David, Vidal Losada, Maria Jesús, Adamo, Barbara, Muñoz Mateu, Montserrat, Galván, Patricia, Barberá, Laura, Cuatrecasas Freixas, Miriam, Christgen, Mathias, Kreipe, Hans, Monge Escartín, Inés, Villagrasa, Patricia, Soy Muner, Dolors, Giarratano, Tommaso, Dieci, Maria Vittoria, Conte, Pierfranco, Harbeck, Nadia, Guarneri, Valentina, Prat Aparicio, Aleix
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/174260
Acceso en línea:https://hdl.handle.net/2445/174260
Access Level:acceso abierto
Palabra clave:Càncer de mama
Receptors d'hormones
Breast cancer
Hormone receptors
Descripción
Sumario:Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene (ERBB2) mRNA.We analyzed ERBB2 expression using a clinically applicable assay in formalin-fixed para n-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association of ERBB2 levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II trial exploring neoadjuvant T-DM1 and 9 in vitro BC cell lines. Finally,

Similares en LA Referencia